Pulse Entdecken nav.journalClub Debatten Trends Forschende

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Start Entdecken nav.journalClub Trends

⌘+K

June 1, 2024

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma

Key Points

Key points are not available for this paper at this time.

Abstract

Belantamab mafodotin had single-agent activity in patients with relapsed or refractory multiple myeloma, a finding that supports further evaluation of the agent in combination with standard-care therapies.

KI fragen

Like

Bookmark

Share

KI fragen

Like

Bookmark

Share

Cite This Study

Hungria et al. (Sat,) studied this question.

synapsesocial.com/papers/68e669a9b6db6435875f575e https://doi.org/https://doi.org/10.1056/nejmoa2405090

Belantamab Mafodotin, Bortezomib, and Dexamethasone for Multiple Myeloma | Synapse

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Treatment of Polycythemia Vera: The Use of Hydroxyurea and Pipobroman in 292 Patients Under the Age of 65 Years1997 · 292 citations
2No Evidence of BCMA Expression Loss or Systemic Immune Impairment after Treatment with the BCMA-Targeted Antibody-Drug Conjugate (ADC) Belantamab Mafodotin (Belamaf) in the DREAMM-1 and DREAMM-2 Trials of Patients with Relapsed/Refractory Multiple Myeloma (RRMM)2022 · 16 citations
3Novel anti–B-cell maturation antigen antibody-drug conjugate (GSK2857916) selectively induces killing of multiple myeloma2014 · 480 citations
4International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma2016 · 3,013 citations
5Leukemic transformation of polycythemia vera2005 · 85 citations